Co-exposure to opiates and HIV/HIV proteins results in enhanced CNS morphological and behavioral deficits in HIV + individuals and in animal models. Opiates with abuse liability, such as heroin and morphine, bind preferentially to and have pharmacological actions through μ-opioid-receptors (MORs). The mechanisms underlying opiate-HIV interactions are not understood. Exposure to the HIV-1 transactivator of transcription (Tat) protein causes neurodegenerative outcomes that parallel many aspects of the human disease. We have also observed that in vivo exposure to Tat results in apparent changes in morphine efficacy, and thus have hypothesized that HIV proteins might alter MOR activation. To test our hypothesis, MOR-mediated G-protein activation was determined in neuroAIDS-relevant forebrain regions of transgenic mice with inducible CNS expression of HIV-1 Tat. G-protein activation was assessed by MOR agonist-stimulated [ , Gly-ol]-enkephalin) and a more clinically relevant agonist, morphine. Tat exposure reduced MOR-mediated G-protein activation in an agonist, time, and regionally dependent manner. Levels of the GPCR regulatory protein β-arrestin-2, which is involved in MOR desensitization, were found to be elevated in only one affected brain region, the amygdala; amygdalar β-arrestin-2 also showed a significantly increased association with MOR by co-immunoprecipitation, suggesting decreased availability of MOR. Interestingly, this correlated with changes in anxiety and fear-conditioned extinction, behaviors that have substantial amygdalar input. We propose that HIV-1 Tat alters the intrinsic capacity of MOR to signal in response to agonist binding, possibly via a mechanism involving altered expression and/or function of β-arrestin-2.
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Introduction
Interactions between opiates and HIV/viral proteins that enhance neuro-acquired immune deficiency syndrome (neuroAIDS) pathology are well documented, both in animal models and in HIV + individuals (Anthony et al., 2008; Bell et al., 2002; Bokhari et al., 2011; Bruce-Keller et al., 2008; Byrd et al., 2011; Dougherty et al., 2002; Fitting et al., 2014; Fitting et al., 2010; Hauser and Knapp, 2014; Pitcher et al., 2014) . The prototypical opiate used in animal studies has been morphine, which is also a major bioactive metabolite of heroin (diacetylmorphine). Interactions between HIV and morphine may also have important consequences for patients using prescribed opiates, because morphine is routinely administered in clinical settings for pain management. Co-administration of morphine and HIV/viral 
